Experts discussed teclistamab's efficacy in multiple myeloma, highlighting real-world data and treatment protocols.
ONCOLOGY® Companion, Volume 39, Supplement 7
Cilta-cel shows promising long-term efficacy in treating relapsed/refractory multiple myeloma, with significant survival rates and manageable safety profiles.
Experts discussed talquetamab's unique mechanism and favorable patient outcomes in relapsed/refractory multiple myeloma.
Experts debate cutting-edge multiple myeloma treatments, exploring pressing data, the most prominent news, and patient cases.
Advertisement
Advertisement
Trending on CancerNetwork
1
KRd Appears to Exhibit Greater Outcomes in Standard-Risk Multiple Myeloma
2
KRd-Based Quadruplets May “Eliminate” Transplant Need for Multiple Myeloma
3
Creating a “Watershed Moment” for Novel Therapeutic Access in Lymphoma
4
Clinical Implications and Future Directions
5
